Connor, Clark & Lunn Investment Management (CC&L)
KNTE

Connor, Clark & Lunn Investment Management (CC&L)’s Kinnate Biopharma Inc. Common Stock KNTE Stock Holding History

Connor, Clark & Lunn Investment Management (CC&L)’s Portfolio KNTE Stock Details KNTE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-76,836
Closed -$182K – 1748
2023
Q4 		$182K Buy
76,836
+24,668
+47% +$43.7K ﹤0.01% 1276
2023
Q3 		$73K Buy
+52,168
New +$125K ﹤0.01% 1312

Other funds holding KNTE

FCMI
Foresite Capital Management IV Larkspur, California $237M AUM 107.53% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
FCMV
Foresite Capital Management V Larkspur, California $271M AUM 309.87% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $508M AUM 163.77% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DAM
Deltec Asset Management New York $677M AUM 31.67% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L)'s KNTE Position: Q1 2024 in Review

Connor, Clark & Lunn Investment Management (CC&L) sold out of Kinnate Biopharma Inc. Common Stock (KNTE) in Q1 2024, closing a stake of 76,836 shares — an estimated $182K sold.

Connor, Clark & Lunn Investment Management (CC&L) first reported a position in KNTE in Q3 2023 and held it in 2 quarters. The position peaked at $182K in Q4 2023. 56 funds tracked by Wall St. Rank hold KNTE as of Q1 2024.

  • Connor, Clark & Lunn Investment Management (CC&L) reported no remaining Kinnate Biopharma Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
  • Connor, Clark & Lunn Investment Management (CC&L) sold 76,836 Kinnate Biopharma Inc. Common Stock shares in Q1 2024, an estimated $182K.
  • Connor, Clark & Lunn Investment Management (CC&L) first reported a position in Kinnate Biopharma Inc. Common Stock in Q3 2023 and held it in 2 quarters.
  • Connor, Clark & Lunn Investment Management (CC&L)'s Kinnate Biopharma Inc. Common Stock position peaked at $182K in Q4 2023.
  • 56 funds tracked by Wall St. Rank held Kinnate Biopharma Inc. Common Stock as of Q1 2024.

Based on Connor, Clark & Lunn Investment Management (CC&L)'s 13F filing for Q1 2024, filed 9 May 2024.